<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866407</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2021000112</org_study_id>
    <nct_id>NCT04866407</nct_id>
  </id_info>
  <brief_title>Topical Eucalyptus Globulus and Mentha x Piperita on Muscle Soreness in Older Adults and the Elderly</brief_title>
  <official_title>Essential Oils and Delayed Onset Muscle Soreness; The Effects of Topical Mentha x Piperita and Eucalyptus Globulus Oils in the Older Adult and Elderly Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects over age 50 with no previous resistance training sessions will be recruited at a&#xD;
      subacute rehabilitation and long term care facility.&#xD;
&#xD;
      Subjects will be asked to perform a series of eccentric upper arm curl exercises under&#xD;
      physician supervision in order to induce muscle soreness. Afterwards, topical oil containing&#xD;
      a 2% dilution of either eucalyptus or peppermint oil in fractionated coconut oil will be&#xD;
      applied to the flexor surface of the proximal non-dominent arm, and plain fractionated&#xD;
      coconut oil to the other arm. This will be repeated at 8 hours and 24 hours after exercise.&#xD;
      Subjects will be asked to report their perceived level of muscle soreness using a visual&#xD;
      analog scale survey 24, 48, and 72 hours after exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects 50 years old and above with no previous resistance training sessions within the past&#xD;
      year will be recruited at a subacute rehabilitation and long-term care facility. A verbal&#xD;
      explanation will be provided to the potential subjects by investigators on-site at the&#xD;
      facility, including the fact that their care at the facility will not be affected by their&#xD;
      decision to participate or not, and if they are interested in proceeding they will be asked&#xD;
      to complete a survey regarding the subject's demographics (gender, age, hand dominance) and&#xD;
      medical history, ensure there are no hypersensitivities to the oils being used, upper&#xD;
      extremity injuries within 1 year, and that they have the functional capacity for exercise of&#xD;
      3.5METs or greater based on the Duke Activity Status Index. If participants pass the&#xD;
      screening process they will again be informed of the study and all potential risks/benefits&#xD;
      prior to signing an informed consent.&#xD;
&#xD;
      Eucalyptus globulus and Mentha x piperita essential oils will be obtained commercially from&#xD;
      SunRose Aromatics (Morrill, Maine), and, individually, will be mixed with carrier oil for&#xD;
      application. SunRose Aromatics is a recommended supplier from the RJ Buckle Clinical&#xD;
      Aromatherapy for Health Professionals course. Fractionated coconut oil will be used as the&#xD;
      carrier oil and also obtained from SunRose Aromatics. A 2% oil mixture for topical&#xD;
      application will be made with essential oils diluted in fractionated coconut oil per&#xD;
      guidelines from the RJ Buckle Clinical Aromatherapy for Health Professionals course&#xD;
      recommendations. This mixture will be prepared directly before application of oils. The&#xD;
      unmixed oils will be stored in a private room with no windows at room temperature at the&#xD;
      Manor Health and Rehabilitation facility (689 W Main St, Freehold, NJ 07728).&#xD;
&#xD;
      Participants will be divided randomly into the Mentha x piperita or the Eucalyptus globulus&#xD;
      group. A 2% oil mixture for topical application will be made with essential oils from SunRise&#xD;
      Aromatics diluted in fractionated coconut oil per guidelines from the RJ Buckle Clinical&#xD;
      Aromatherapy for Health Professionals course recommendations. Physician-supervised eccentric&#xD;
      exercise of the elbow flexors will be performed based on an adaptation of the method&#xD;
      described by Weber. Free weight dumbbells will provide resistance. The subject will be&#xD;
      instructed to prolong the extension aspect of the curl to be five seconds long. They will&#xD;
      repeat this motion for 10 or more repetitions until exhaustion, either due to the participant&#xD;
      feeling they can no longer tolerate the five second eccentric aspect of the exercise or the&#xD;
      investigator identifying that their form has faltered. If subjects reach exhaustion after the&#xD;
      10 repetitions minimum, they will rest for 1 minute. If they are unable to complete 10&#xD;
      repetitions at this weight, the resistance will be decreased to the next lowest weight and&#xD;
      they will continue until exhaustion. This will continue until subjects reach exhaustion with&#xD;
      the lowest resistance weight. Immediately following exercise, the participants will have the&#xD;
      respective oil applied topically to their left upper extremity by the investigator. Their&#xD;
      right upper extremity will serve as the control and no essential oil will be applied.&#xD;
      Investigators will apply the oil without any use of massage technique and to only apply very&#xD;
      superficial pressure. This application will be repeated 8 hours after exercise, when DOMS has&#xD;
      been known to initiate, and at 24 hours after exercise, when DOMS may begin to peak.&#xD;
&#xD;
      Subject outcomes will be based on a self-reported visual analog scale, which has previously&#xD;
      been shown to have validity in subjectively quantifying perceived muscle soreness and used in&#xD;
      prior studies. These outcomes will be recorded by investigators for both the intervention and&#xD;
      control upper extremity at 24, 48, and 72 hours post-exercise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perceived Muscle Soreness</measure>
    <time_frame>24 hours after exercise</time_frame>
    <description>Perceived soreness using a visual analog scale rating from '0' to '100'; a higher score indicates more muscle soreness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Muscle Soreness</measure>
    <time_frame>48 hours after exercise</time_frame>
    <description>Perceived soreness using a visual analog scale rating from '0' to '100'; a higher score indicates more muscle soreness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Muscle Soreness</measure>
    <time_frame>72 hours after exercise</time_frame>
    <description>Perceived soreness using a visual analog scale rating from '0' to '100'; a higher score indicates more muscle soreness</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Muscle Soreness</condition>
  <arm_group>
    <arm_group_label>Mentha x piperita</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A diluted solution of Mentha x piperita in carrier oil will be applied to the subject's interventional extremity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eucalyptus globulus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A diluted solution of Eucalyptus globulus in carrier oil will be applied to the subject's interventional extremity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Each participant will have one extremity that receives no essential oil intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mentha x piperita</intervention_name>
    <description>2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.</description>
    <arm_group_label>Mentha x piperita</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eucalyptus globulus</intervention_name>
    <description>2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.</description>
    <arm_group_label>Eucalyptus globulus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects 50 years or older with no previous resistance training sessions in the past&#xD;
             year&#xD;
&#xD;
          -  Duke Activity Screening Index functional capacity of at least 3.5 metabolic&#xD;
             equivalents or greater&#xD;
&#xD;
          -  currently admitted at the Manor Health and Rehabilitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of musculoskeletal injury or weight bearing restrictions to the upper&#xD;
             extremities within the past year&#xD;
&#xD;
          -  known adverse reaction or allergy to the essential oils or hypersensitivities to&#xD;
             fragrances&#xD;
&#xD;
          -  open upper extremity wounds or history of upper extremity skin grafts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeeshan Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers RWJMS Department of Family Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sydney Asselstine, MD</last_name>
    <phone>7322942540</phone>
    <email>sasselst@centrastate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Manor Health and Rehabillitation - CentraState</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sydney Asselstine, MD</last_name>
      <phone>732-294-2540</phone>
      <email>sasselst@centrastate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zeeshan Khan, MD</last_name>
      <phone>7322942540</phone>
      <email>zkhan@centrastate.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zeeshan Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Raymond, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sydney Asselstine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anand Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.acsm.org/blog-detail/acsm-certified-blog/2018/02/01/exercise-preparticipation-screening-removing-barriers-initiating-exercise</url>
    <description>ACSM's New Exercise Preparticipation Screening</description>
  </link>
  <reference>
    <citation>Meamarbashi A. Herbs and natural supplements in the prevention and treatment of delayed-onset muscle soreness. Avicenna J Phytomed. 2017 Jan-Feb;7(1):16-26. Review.</citation>
    <PMID>28265543</PMID>
  </reference>
  <reference>
    <citation>Cheung K, Hume P, Maxwell L. Delayed onset muscle soreness : treatment strategies and performance factors. Sports Med. 2003;33(2):145-64. Review.</citation>
    <PMID>12617692</PMID>
  </reference>
  <reference>
    <citation>Hanif, M., Nisar, S., Khan, G., Mushtaq, Z., Zubair, M. (2019) Essential Oils. Essential Oil Research. Springer, Cham. doi: 10.1007/978-3-030-16546-8_1</citation>
  </reference>
  <reference>
    <citation>Baser, K., and Buchbauer, G. (2009) Handbook of Essential Oils: Science, Technology, and Applications. CRC Press LLC.</citation>
  </reference>
  <reference>
    <citation>de Sousa AA, Soares PM, de Almeida AN, Maia AR, de Souza EP, Assreuy AM. Antispasmodic effect of Mentha piperita essential oil on tracheal smooth muscle of rats. J Ethnopharmacol. 2010 Jul 20;130(2):433-6. doi: 10.1016/j.jep.2010.05.012. Epub 2010 May 19.</citation>
    <PMID>20488237</PMID>
  </reference>
  <reference>
    <citation>Kehili, S. et. al. Peppermint (Mentha piperita L.) essential oil as a potent anti-inflammatory, wound healing and anti-nociceptive drug. European Journal of Biological Research. 2020; 10(2):132-149. Doi: 10.5281/zenodo.3831042</citation>
  </reference>
  <reference>
    <citation>Vuong QV, Chalmers AC, Jyoti Bhuyan D, Bowyer MC, Scarlett CJ. Botanical, Phytochemical, and Anticancer Properties of the Eucalyptus Species. Chem Biodivers. 2015 Jun;12(6):907-24. doi: 10.1002/cbdv.201400327. Review.</citation>
    <PMID>26080737</PMID>
  </reference>
  <reference>
    <citation>Liapi C, Anifandis G, Chinou I, Kourounakis AP, Theodosopoulos S, Galanopoulou P. Antinociceptive properties of 1,8-Cineole and beta-pinene, from the essential oil of Eucalyptus camaldulensis leaves, in rodents. Planta Med. 2007 Oct;73(12):1247-54. Epub 2007 Sep 24. Erratum in: Planta Med. 2008 Jun;74(7):789. Anifantis, Georgios [corrected to Anifandis, Georgios].</citation>
    <PMID>17893834</PMID>
  </reference>
  <reference>
    <citation>Mascolo, N. et al. Biological screening of Italian Medicinal Plants for anti-inflammatory activity. Phytother Res. 1987; 1(1)28-31. Doi: 10.1002/ptr.2650010107</citation>
  </reference>
  <reference>
    <citation>Jun YS, Kang P, Min SS, Lee JM, Kim HK, Seol GH. Effect of eucalyptus oil inhalation on pain and inflammatory responses after total knee replacement: a randomized clinical trial. Evid Based Complement Alternat Med. 2013;2013:502727. doi: 10.1155/2013/502727. Epub 2013 Jun 18.</citation>
    <PMID>23853660</PMID>
  </reference>
  <reference>
    <citation>Göbel H, Schmidt G, Soyka D. Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters. Cephalalgia. 1994 Jun;14(3):228-34; discussion 182.</citation>
    <PMID>7954745</PMID>
  </reference>
  <reference>
    <citation>Göbel H, Schmidt G, Dworschak M, Stolze H, Heuss D. Essential plant oils and headache mechanisms. Phytomedicine. 1995 Oct;2(2):93-102. doi: 10.1016/S0944-7113(11)80053-X.</citation>
    <PMID>23196150</PMID>
  </reference>
  <reference>
    <citation>Weber MD, Servedio FJ, Woodall WR. The effects of three modalities on delayed onset muscle soreness. J Orthop Sports Phys Ther. 1994 Nov;20(5):236-42.</citation>
    <PMID>7827630</PMID>
  </reference>
  <reference>
    <citation>Zainuddin Z, Newton M, Sacco P, Nosaka K. Effects of massage on delayed-onset muscle soreness, swelling, and recovery of muscle function. J Athl Train. 2005 Jul-Sep;40(3):174-80.</citation>
    <PMID>16284637</PMID>
  </reference>
  <reference>
    <citation>Rey E, Lago-Peñas C, Lago-Ballesteros J, Casáis L. The effect of recovery strategies on contractile properties using tensiomyography and perceived muscle soreness in professional soccer players. J Strength Cond Res. 2012 Nov;26(11):3081-8. doi: 10.1519/JSC.0b013e3182470d33.</citation>
    <PMID>22210472</PMID>
  </reference>
  <reference>
    <citation>Tisserand, R., Young, R., &amp; Williamson, E. M. (2014). The Skin. In Essential oil safety: A guide for health care professionals (pp. 69-98). Edinburgh: Churchill Livingstone/Elsevier</citation>
  </reference>
  <reference>
    <citation>Tisserand, R., Young, R., &amp; Williamson, E. M. (2014). Essential Oil Profiles: Eucalyptus globulus. In Essential oil safety: A guide for health care professionals Edinburgh: Churchill Livingstone/Elsevier.</citation>
  </reference>
  <reference>
    <citation>Tisserand, R., Young, R., &amp; Williamson, E. M. (2014). Essential Oil Profiles: Mentha x piperita. In Essential oil safety: A guide for health care professionals (pp. 69-98). Edinburgh: Churchill Livingstone/Elsevier. (pp. 387-391)</citation>
  </reference>
  <reference>
    <citation>Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011 Aug;43(8):1575-81. doi: 10.1249/MSS.0b013e31821ece12.</citation>
    <PMID>21681120</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Sydney Asselstine, MD</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <keyword>Essential Oils</keyword>
  <keyword>Muscle Soreness</keyword>
  <keyword>Mentha x piperita</keyword>
  <keyword>Eucalyptus globulus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Do not plan to.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

